Duyuru • Jul 23

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. announced it has significantly expanded its SAB with the appointment of renowned neurologists, neuroscientists, and epileptologists. Working together with the SAB, Ovid looks to optimize its research, translation and clinical development plans. Members of the Ovid Therapeutics Scientific Advisory Board: Robert Langer is the chair of Ovid’s Scientific and Clinical Advisory Board. Dr. Langer is one of 10 Institute Professors at MIT and has written over 1,500 scholarly articles. He is also the most cited engineer in history (h-index 286, with over 338,000 citations according to Google Scholar). He has served as the chair of the U.S. Food and Drug Administration’s Science Board, and has been recognized with over 220 awards, including the United States National Medals of both Science and Technology and Innovation. Dr. Langer was named as one of the 20 most important people in biotechnology by Discover magazine and one of 15 innovators who will reinvent the company's future by Forbes. TIME and CNN named him as one of the most important people in America and one of the 18 top people in science or medicine in America. He was also recognized as one of the world’s 25 most important individuals in biotechnology by Forbes and by BioWorld. Dr. Langer holds 35 honorary doctorate degrees and has been elected to the National Academies of Medicine, Engineering, Sciences and Inventors. Imad Najm, M.D., is the Vice Chair for Strategy and Development at the Cleveland Clinic Neurological Institute and Director of the Cleveland Clinic Epilepsy Center (2006-present). He is an Adjunct Professor in the Department of Biomedical Engineering at Case Western Reserve University and the Department of Neurobiology at Kent State University. Dr. Najm also has served as the Co-Director of Basic Sciences and Neurosciences at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, Head of Adult Epilepsy and Director of the Epilepsy and Clinical Neurophysiology fellowship at Cleveland Clinic. His research over the last 34 years has been funded by the National Institutes of Health (NIH), the U.S. Department of Defense, the Epilepsy Foundation, and multiple philanthropic donations. He has published 275 peer-reviewed papers in multiple journals, authored or co-authored many book chapters and edited two textbooks. He has lectured on epilepsy in more than 30 countries and organized international symposia, courses and workshops in more than 15 countries. His main areas of research interest include the mechanisms of disease (epileptogenicity/epileptogenesis), clinical and imaging correlates, and surgical management of focal cortical dysplasia. He has been teaching Basic Neurosciences at Cleveland Clinic Lerner College of Medicine since 2005. He has mentored and co-mentored more than 300 epilepsy fellows and graduate students. Dr. Najm designed and co-directed the Neuroscience Curriculum at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Dr. Najm received his M.D. from Saint Joseph University in Beirut, Lebanon. He had post-graduate training in neurobiology at the University of Southern California and the University of California, Irvine. He also did post-graduate training in neurology, epilepsy, and clinical neurophysiology at Cleveland Clinic. Raman Sankar, M.D., Ph.D., is the Emeritus Chief of Pediatric Neurology at UCLA Health. He is an elected Fellow of the American Academy of Neurology and the American Epilepsy Society, and a member of the American Pediatric Society, the Child Neurology Society and the Society for Neuroscience. He has served on several editorial boards of journals dedicated to epilepsy research and has also served on several NINDS-NIH review committees. He is a recipient of the Founders Award of the American Epilepsy Society, the highest honor conferred by the Society in recognition of outstanding lifetime achievement in the field of epilepsy. Board certified in neurology with special qualification in child neurology, he has dedicated over three decades to advancing research and clinical practices in epilepsy and child neurology. Dr. Sankar holds an M.D. from Tulane University and a Ph.D. in medicinal chemistry from the University of Washington. Jamie Maguire, Ph.D., is Professor of Neuroscience at Tufts University School of Medicine and was named the Kenneth and JoAnn G. Wellner Professor in Neuroscience in 2019. Dr. Maguire is a member of the Graduate Biomedical Sciences Pharmacology and Neuroscience programs. She is the Director of the Building Diversity in Biomedical Sciences (BDBS) program and has a strong commitment to increasing diversity, equity, and inclusion in STEM and beyond. Her current research focuses on a systems physiology approach to the study of neurological and neuropsychiatric diseases, focusing on epilepsy and mood disorders, which has led to successful clinical trials for postpartum depression treatments. She received a BS in neuroscience and BA in the history of art and architecture from the University of Pittsburgh and her Ph.D. in neuroscience from George Washington Univ ersity. Dr. Maguire trained as a postdoctoral fellow at UCLA investigating the ability of steroid hormones and neurosteroids to modulate GABAergic inhibition and their impact on mood disorders and epilepsy. Jeffrey Noebels, M.D., Ph.D., is the Cullen Trust for Health Care Endowed Chair in Neurogenetics, and Professor of Neurology, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine, where he directs the Blue Bird Circle Developmental Neurogenetics Laboratory. Dr. Noebels is a past president of the American Epilepsy Society and fellow of the American Association for the Advancement of Science. Dr. Noebels’ research involves understanding how single genes regulate neuronal excitability and network synchronization within the central nervous system. His lab's recent work on mouse models of Alzheimer’s Disease and glioblastoma-related epilepsy has provided pioneering insights into the role of hyperexcitability in cognitive decline and umorigenesis. He received a BA from Reed College, an M.D. from Yale University School of Medicine, and his Ph.D. from Stanford University. Dr. Noebels conducted his neurology residency at Massachusetts General Hospital, and a post-doctoral fellowship at Harvard University. Board certified in neurology by the American Board of Psychiatry and Neurology, his research interests include gene control of neuronal excitability within the developing central nervous system, inherited neurological diseases, and epilepsy.

Duyuru • Jul 01

Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule

Ovid Therapeutics Inc. and Graviton Bioscience Corporation announced the results from their Phase 1 healthy volunteer study evaluating the safety, tolerability, and pharmacokinetic (PK) profile of multiple ascending doses of OV888/GV101 capsule. Ovid and Graviton Bioscience plan to progress to a Phase 2 clinical study in cerebral cavernous malformations (CCM) later this year. Summary of Phase 1 Topline Findings: The Phase 1 study was a single-center, double-blinded, randomized, placebo-controlled, multiple ascending dose (MAD) trial to evaluate the safety, tolerability, and PK profile of OV888/GV101 capsule in healthy adult volunteers. OV888/GV101 capsule or placebo was administered once daily for seven days. The MAD cohorts evaluated doses of 100 mg, 200 mg, 400 mg, and 600 mg. OV888/GV101 capsule met the study’s primary safety and tolerability objectives and characterized its PK properties. Well tolerated at all tested doses. There were no serious adverse events (SAEs) and no participants met the preset trial stopping criteria. All drug-associated clinical adverse events (AEs) were mild (Grade 1) and resolved. The most commonly reported clinical AE was headache, which occurred in 23% of participants. All participants reporting headaches had transient cases, which resolved. One subject discontinued the study early due to mild headache and nausea, which resolved after study drug discontinuation. Most clinical AEs resolved within 24 hours, all resolved within the study period. There were no AEs reported in the placebo cohort. Target engagement achieved. There was a dose dependent decrease in proinflammatory cytokines IL-17 and IL-21 secretion by stimulated peripheral blood mononuclear cells. These decreases are markers of selective ROCK2 inhibition. These findings indicate that OV888/GV101 is biologically active in humans at the target clinical dose and elicits a pharmacodynamic response. Exposure and half-life findings supportive of daily dosing. Topline data show a dose dependent increase in Cmax and AUC0-24 up to the 400 mg target dose. The average half-life is approximately 12 hours suggesting that OV888/GV101 capsule may be well suited for once daily dosing. Laboratory results. In the study period, there were two asymptomatic laboratory findings rated Grade 2 or higher, which occurred in at least 5% of treated subjects relative to placebo. Increases in total bilirubin without direct hyperbilirubinemia were reported in 30% of participants. These elevations were clinically insignificant and are consistent with the understood effect of ROCK2 inhibition on UGT1A1 enzyme. Importantly, no concurrent liver enzyme elevations were observed. Creatine phosphokinase elevations without muscle pain or weakness were reported in 7% of participants. There were no reported related clinical impacts for either laboratory finding, and all participants normalized during the study period. Ovid and Graviton expect to initiate a Phase 2 proof-of-concept study in people living with CCMs in the second half of 2024. Additionally, under the collaboration agreement between Ovid and Graviton, the parties have agreed to develop an intravenous formulation of OV888/GV101 for undisclosed neurological indications.

Toplam Hissedar Getirisi	-34.0%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Segment	Temettü Verimi
Şirket (OVID)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.1%
Sektör Ortalaması (Biotechs)	2.4%
Analist tahmini (OVID) (3 yıla kadar)	0%

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/06/28 07:03
Gün Sonu Hisse Fiyatı	2026/06/26 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

Analist	Kurum
Kalpit Patel	B. Riley Securities, Inc.
Madison Wynne El-Saadi	B. Riley Securities, Inc.
Thomas Shrader	BTIG

Ovid Therapeutics Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

OVID: Index Inclusion And New Psychosis Indications Will Support Bullish Outlook

Ovid Therapeutics Inc Announces Appointment of Anna Greka to Board of Directors and Committee Changes, Effective June 15, 2026

Consensus revenue estimates decrease by 39%, EPS upgraded

First quarter 2026 earnings released: US$0.13 loss per share (vs US$0.14 loss in 1Q 2025)

Ovid Therapeutics Inc., Annual General Meeting, Jun 10, 2026

Long Term Epilepsy And Psychosis Pipeline Will Reshape Prospects For This Undervalued Biotech

New major risk - Revenue and earnings growth

Price target increased by 7.9% to US$4.45

Full year 2025 earnings: EPS and revenues exceed analyst expectations

Expanding Neurology Pipeline And Extended Cash Runway Will Support Powerful Long Term Upside Potential

Ovid Therapeutics Inc. announced that it expects to receive $59.99992 million in funding from a group of investors

Now 22% overvalued

Now 29% overvalued after recent price rise

New major risk - Shareholder dilution

New major risk - Share price stability

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (Kcc2), Ov350 Intravenous (Iv)

Ovid Therapeutics Inc. Appoints Petra Kaufmann as Chief Medical Officer

Third quarter 2025 earnings: EPS and revenues miss analyst expectations

Ovid Therapeutics Inc. Announces Board Changes

Price target increased by 13% to US$3.85

Ovid Therapeutics Inc. announced that it has received $80.8108 million in funding from Janus Henderson Group plc, RA Capital Management, L.P., Blue Owl Healthcare Opportunities, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC

Ovid Therapeutics Inc. Announces Positive Topline Results for the Next-Generation Gababatrin (Vg) Inhibitor, OV329

Price target decreased by 11% to US$2.85

Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders

Consensus revenue estimates increase by 2,024%

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

New major risk - Share price stability

Price target decreased by 10% to US$2.88

Consensus revenue estimates increase by 22%

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Ovid Therapeutics Inc., Annual General Meeting, Jul 09, 2025

New minor risk - Share price stability

Consensus revenue estimates decrease by 16%

Price target decreased by 15% to US$2.88

Consensus revenue estimates decrease by 30%, EPS upgraded

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Ovid Therapeutics Inc. Appoints Stelios Papadopoulos to Its Board of Directors and Member of Audit and Compensation Committees

Ovid Therapeutics Receives Non-Compliance Letter from Nasdaq Regarding Minimum Closing Bid Price

High number of new and inexperienced directors

Consensus revenue estimates increase by 45%, EPS downgraded

New major risk - Financial position

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new and inexperienced directors

Ovid Therapeutics Appoints Dr. Amanda Banks, as Chief Development Officer

Ovid Therapeutics Inc. Expands Scientific Advisory Board

Ovid Therapeutics Inc. Announces That eNeuro Publishes Findings on the Anti-Convulsant Properties of OV329 and Its Potential Effectiveness in Treatment-Resistant Seizures

Ovid Therapeutics Inc.(NasdaqGS:OVID) dropped from Russell Small Cap Comp Value Index

Ovid Therapeutics Inc. and Graviton Bioscience Corporation Announce Topline Data from A Phase 1 Clinical Trial Studying OV888/GV101 Capsule

Consensus revenue estimates decrease by 87%, EPS upgraded

Consensus revenue estimates fall by 80%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Ovid Therapeutics Inc., Annual General Meeting, Jun 06, 2024

Ovid Therapeutics: Data Readouts For Rare Epileptic Indications Late 2024

President recently bought US$50k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus revenue estimates increase by 1,902%

We Think Ovid Therapeutics (NASDAQ:OVID) Can Afford To Drive Business Growth

Consensus revenue estimates increase by 51%

Price target increased by 20% to US$6.00

Consensus revenue estimates increase by 48%

Ovid Therapeutics Inc. Announces Changes to Its Board

Companies Like Ovid Therapeutics (NASDAQ:OVID) Are In A Position To Invest In Growth

Consensus revenue estimates increase by 14%

Price target increased by 7.1% to US$5.00

Consensus revenue estimates increase by 60%, EPS downgraded

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Here's Why We're Watching Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Situation

Ovid Therapeutics Expands Epilepsy Development Expertise with New Appointments

Ovid Therapeutics Doses Healthy Volunteers with OV329 in Phase 1 Trial

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.17 loss per share (vs US$0.17 loss in 3Q 2021)

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated